Article
The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation.
Annals of diagnostic pathology - 1 Feb 2020
Ingenwerth Marc, Goetz Moritz, Schmid Kurt W, Theurer Sarah
Abstract excerpt
INTRODUCTION: Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine neoplasia of the thyroid with 10 year overall survival of 50% and limited therapeutic options. High tumor mutational burden because of microsatellite instability (MSI) seems to be a predictor of response to immune checkpoint inhibitor therapy in different tumors. Therefor in 2017 the U.S. Food and Drug Administration (FDA) permitted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
